{"id":"NCT03659929","sponsor":"Arbor Pharmaceuticals, Inc.","briefTitle":"Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate","officialTitle":"A Multicenter, Fixed-Dose, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of AR19 (Amphetamine Sulfate) in Adult Subjects (Ages 18-55) With Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-09-18","primaryCompletion":"2019-04-12","completion":"2019-04-12","firstPosted":"2018-09-06","resultsPosted":"2024-09-03","lastUpdate":"2024-09-03"},"enrollment":320,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Attention Deficit Hyperactivity Disorder"],"interventions":[{"type":"DRUG","name":"Amphetamine Sulfate","otherNames":["AR19"]},{"type":"DRUG","name":"Placebo","otherNames":["inactive drug"]}],"arms":[{"label":"Arm 1: 20 mg/day","type":"EXPERIMENTAL"},{"label":"Arm 2: 40 mg/day","type":"EXPERIMENTAL"},{"label":"Arm 3: Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the AR19.004 study is to assess the efficacy of AR19 compared to placebo using the Adult ADHD Investigator Symptom Rating Scale (AISRS)","primaryOutcome":{"measure":"Change From Baseline in Severity of Attention Deficit Hyperactivity (ADHD) Symptoms","timeFrame":"Week 5 (Visit 7)","effectByArm":[{"arm":"Placebo","deltaMin":-11.1,"sd":1.28},{"arm":"Amphetamine Sulfate (20 mg/Day)","deltaMin":-18.2,"sd":1.28},{"arm":"Amphetamine Sulfate (40 mg/Day)","deltaMin":-18.1,"sd":1.27}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":31,"countries":["United States"]},"refs":{"pmids":["34428356"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":106},"commonTop":["Headache","Decreased Appetite","Insomnia","Dry Mouth","Nasopharyngitis"]}}